摘要
目的研究哌拉西林/他唑巴坦治疗急性卒中相关性肺炎的临床疗效。方法 83例因急性卒中而并发经病原学证实的卒中相关性肺炎患者,随机分为哌拉西林/他唑巴坦治疗组和头孢他啶对照组,疗程均为14 d,治疗后复查痰培养。结果治疗组与对照组临床有效率、细菌清除率分别为90.48%、92.86%和70.73%、75.61%,两组临床有效率与细菌清除率差异有统计学意义(P<0.05)。结论哌拉西林/他唑巴坦治疗急性卒中相关性肺炎效果好,可作为治疗急性卒中相关性肺炎患者的经验用药。
OBJECTIVE To evaluate the clinical efficacy of Piperacillin/tazobactam for acute stroke-associated pneumonia. METHODS 83 cases of acute stroke^associated pneumonia patients who were microbiologically diagnosed were randomized into Piperacillin/tazohactam group and Ceftazidime group, and sputum culture was undertaken twice after treatment. RESULTS The total efficacy rates and bacterial clean rates in Piperacillin/ tazobactam group and Ceftazidime group were 90.48%, 92. 86% and 70. 73%, 75. 61% respectively, and the differences between the two groups were statistically significant. CONCLUSIONS It suggests that Piperaeillin/ tazobactam is a more eJfective drug for acute stroke-associated pneumonia.
出处
《中华医院感染学杂志》
CAS
CSCD
北大核心
2010年第12期1787-1788,共2页
Chinese Journal of Nosocomiology
关键词
脑梗死后肺炎
哌拉西林/他唑巴坦
Acute stroke-associated pneumonia
Piperacillin/Tazobactam
